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Background and Objective. Bronchoalveolar coagulopathy is a characteristic feature of pulmonary inﬂammation. We compared
bronchoalveolar and systemic levels of coagulation in patients who did and patients who did not develop ventilator-associated
lung injury (VALI). Methods. Secondary analysis of a randomized controlled trial evaluating the eﬀect of lower tidal volumes
versus conventional tidal volumes in patients without acute lung injury or acute respiratory distress syndrome at the onset of
mechanical ventilation. Results. Ten patients with VALI and 10 random control patients without lung injury during the course of
mechanical ventilation, but all ventilated with conventional tidal volumes, were compared. Patients who developed VALI showed
both bronchoalveolar activation of coagulation (increase in thrombin–antithrombin complex levels P<0.001 versus baseline) and
inhibition of ﬁbrinolysis (decline in plasminogen activator activity P<0.001 versus baseline). The later seemed to be dependent
on higher levels of plasminogen activator inhibitor type 1 (P = 0.001 versus baseline). Patients who developed VALI also showed
elevatedsystemicthrombin-antithrombincomplexlevelsanddecreasedsystemicplasminogenactivatoractivitylevels.Conclusions.
VALI is characterized by bronchoalveolar coagulopathy. Systemic and bronchoalveolar coagulopathy at the onset of mechanical
ventilation may be a risk factor for developing VALI in patients ventilated with conventional tidal volumes.
1.Introduction
There is indisputable evidence that mechanical ventilation
hasthepotentialtoaggravatelunginjury.Indeed,tworando-
mized controlled clinical trials conﬁrm the existence of so-
called ventilator-associated lung injury (VALI) in patients
with acute lung injury or acute respiratory distress syndrome
(ALI/ARDS) by showing reduced morbidity and mortality
withlung-protectivemechanicalventilationusinglowertidal
volumes [1, 2]. Current guidelines, therefore, now support
theuseoflowertidalvolumesinpatientswithALI/ARDS[3].
There is increasingly more evidence supporting the use
of lower tidal volume in critically ill patients without ALI/
ARDS. Nonprotective forms of mechanical ventilation po-
tentiate the local inﬂammatory response in patients with
ALI/ARDS via local upregulation of proinﬂammatory medi-
ators [4, 5]. Several small studies, mainly focusing on the
eﬀects of short-term mechanical ventilation in the operating
theater, have extended these data to patients not suﬀering
from ALI/ARDS. Nonprotective mechanical ventilation set-
tings result in procoagulant activity in the pulmonary com-
partment and systemic upregulation of proinﬂammatory
cytokines, although the results of studies were not always
consistent[6].Resultsfromrecentcohortstudiessuggestthat
mechanical ventilation with conventional tidal volumes may
cause or contribute to development of VALI in critically ill
patients who do not have ALI/ARDS at the onset of mechan-
ical ventilation [7, 8]. Finally, we recently stopped a random-
ized controlled trial comparing conventional tidal volumes
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at onset of mechanical ventilation prematurely because de-
velopment of VALI during the course of mechanical ventila-
tion was higher in the group treated with conventional tidal
volumes as compared to the lower tidal volume group [9].
Alveolar ﬁbrin deposition is an important feature of pul-
monary inﬂammation. The mechanisms that contribute to
disturbedbronchoalveolarﬁbrinturnoverarelocalizedtissue
factor- (TF-) mediated thrombin generation and depression
ofﬁbrinolysis,causedbytheincreaseofinhibitorsoftheplas-
minogen activator, in particular plasminogen activator inhi-
bitor type 1 (PAI-1) [10]. These eﬀects on pulmonary coagu-
lation and ﬁbrinolysis are regulated by various proinﬂam-
matory cytokines and are similar to those found in the
intravascular spaces during severe systemic inﬂammation.
We showed before that the use of conventional tidal volumes
during a short course of mechanical ventilation because of a
surgicalprocedurealsocausespulmonarycoagulopathy[11].
Ventilator-induced coagulopathy in this study was large-
ly prevented with the use of lower tidal volumes.
In the present analysis, we performed a secondary anal-
ysis of the recently performed clinical trial on conventional
versus lower tidal volumes in patients without ALI/ARDS. In
the present analysis we compared patients who did and pa-
tients who did not develop VALI in the conventional tidal
volume arm of that study, with respect to bronchoalveolar
and systemic coagulopathy. Our aim was to determine
whether development of VALI with the use of conventional
tidal volumes is characterized by pulmonary coagulopathy
alike the use of conventional tidal volumes with short-term
mechanical ventilation.
2. Patientsand Methods
2.1.Patients. Intheoriginalstudy150patientswereincluded
at the intensive care units of one regional teaching hospital
and one academic in The Netherlands. Patients were eligible
if they did not meet the North-American European Con-
sensus Conference criteria for ALI/ARDS [12] and needed
mechanical ventilation for an anticipated duration of at least
3 days as described previously. Randomization, data and
sample collection had to be started within 36 hours of initia-
tion of mechanical ventilation. Exclusion criteria were: age
under 18 years, participation in other clinical trials, preg-
nancy,increaseduncontrollableintracranialpressure,history
of severe chronic obstructive pulmonary disease or severe
restrictive pulmonary disease, history of pneumectomy or
lobectomy, use of immunosuppressive agents (>100mg hy-
drocortisone per day), pulmonary thromboembolism, and
previous randomization in this study. The protocol was ap-
proved by the medical ethics committee of both hospitals,
and written informed consent was obtained from the patient
or closest relative before the start of the study.
2.2. Mechanical Ventilation. The study protocol was as des-
cribed previously. In short, the volume control mode was
used for mechanical ventilation. The target tidal volume was
calculated as 10 or 6mL times the predicted body weight
as described previously. The inspiratory ﬂow rate was main-
tained at 40 liters per minute. As soon as patients were able
to breathe spontaneously with assistance, the pressure sup-
port mode was used. In this case, the pressure support was
adjusted in order to reach the target tidal volume. As soon
as patients were ready to be weaned from the ventilator the
amount of support was decreased at discretion of the attend-
ingphysician.IfapatientmettheNorth-AmericanEuropean
Consensus Conference criteria [12] for ALI/ARDS, the
attendingintensivecarephysicianwasadvisedtoventilatethe
patient with a lung-protective mechanical ventilation stra-
tegy allowing tidal volumes of 6mL per kilogram predicted
body weight in the pressure control mode (according to
the local institutional protocol for mechanical ventilation in
patients with ALI/ARDS) for the remaining ventilation peri-
od.
2.3. Data Collection. Demographic data, ventilation param-
eters, and clinical and radiological data were recorded each
second day, for calculation of acute physiology and chronic
healthevaluation-(APACHE-)IIscore,sequentialorganfail-
ure assessment (SOFA) score, and lung injury score (LIS). In
addition, blood gas parameters were recorded until the pa-
tient was weaned from the ventilator.
On the day of enrollment and each second day until the
patient was weaned from the ventilator, a bronchoalveolar
minilavage was performed for measurement of levels of
coagulation and ﬁbrinolysis. Minilavage was performed as
described previously [13]. In short, a 20mL syringe was
ﬁlled with 0.9% saline and attached to a 50cm 14Fr tracheal
suction catheter. The catheter was inserted in the orotracheal
tube and advanced until signiﬁcant resistance was encoun-
tered. Saline was instilled over 10 seconds and immediately
aspirated. The recovery was 4–8mL in general. For coag-
ulation assays, EDTA was added to the lavage ﬂuids to a
ﬁnal concentration of 1.7mM. The recovered ﬂuid was cen-
trifuged at 1,500×gf o r1 0m i n u t e sa t4 ◦C. The supernatant
was collected and stored at −80◦C until measurements were
performed. Citrated (0.109M) blood samples were drawn
prior to each lavage. Samples were centrifuged at 1,500×g
for 10 minutes at 4◦C; supernatants were stored at –80◦C.
2.4. Measurements. Thrombin-antithrombin complex
(TATc), TF, and PAI-1 were measured using speciﬁc com-
mercially available ELISA’s according to the instructions
of the manufacturer (TATc: Behringwerke AG, Marburg,
Germany; TF: American Diagnostics, Greenwich, CT, USA;
PAI-1: TintElize PAI-1, Biopool, Umea, Sweden). The levels
of factor VIIa were determined by using previously described
enzyme capture assay for determining factor (F) VIIa activity
[14]. Brieﬂy, solid-phase bound monoclonal antibodies rose
againstrecombinantFVIIaenabledcapturingofFVIIa.Inthe
next step, bound FVIIa was allowed to convert a ﬂuorogenic
substrate during incubation, which is linearly correlated
with FVIIa concentrations. Plasminogen activator activity
(PAA) was measured by an amidolytical assay [15]. Brieﬂy,
25µL of plasma was mixed to a ﬁnal volume of 250µLw i t h
0.1M TrisHCl, pH 7.5, 0.1% (v/v) Tween-80, 0.3mM S-2251
(Chromogenix, M¨ olndal, Sweden), 0.13M plasminogen and
0.12mg/mL CNBr fragments of ﬁbrinogen (Chromogenix,
M¨ olndal, Sweden). The results are expressed as IU/mL.Critical Care Research and Practice 3
2.5. Statistical Analysis. The original study was stopped after
the second interim analysis as the incidence of ALI/ARDS
after randomization was signiﬁcantly higher in the conven-
tional tidal volume group. By that time 74 patients were
randomized to the conventional tidal volume arm and 76 to
the lower tidal volume arm. The aim of the present study was
to investigate the procoagulant and ﬁbrinolytic activity in
patients who developed VALI. In the analysis we included all
patients with VALI from the conventional tidal volume arm
(n = 10).Fromtheremaining64patientswithoutVALIfrom
the conventional tidal volume arm, we included 10 patients
as controls. These patients were randomly selected by SPSS.
T h er e q u i r e ds a m p l es i z eo f1 0w a sc a l c u l a t e df r o md a t a
from our previous investigations on pulmonary hemostasis
in patients undergoing elective surgery [11]. To detect dif-
ferences in bronchoalveolar TATc concentrations in patients
with and without VALI at a two-sided signiﬁcance levels
of 5% with a power of 80%, the number of patients to be
included in each group was 9.
Data are presented as mean with standard deviation for
parametricdataorasmedianswithinterquartilerange[IQR]
for non-parametric data. Baseline comparisons between
groups were made by the Student’s t-test, Mann-Whitney U
test, Chi-square test, or Fisher exact test where appropriate.
Levels of coagulation/ﬁbrinolysis at baseline were analyzed
with the Mann-Whitney U test. To study changes over
time, a linear mixed model was constructed by adding time
and randomization group as a factors in the model. The
interaction between time and randomization group in this
model was used to study diﬀerences over time between
groups. A two-tailed P value <0.05 was considered as statis-
tically signiﬁcant. Data were analyzed using SPSS, version
14.02 (SPSS Inc, Chicago, IL, USA).
3. Results
3.1. Patients. Ten patients developed VALI after initiation of
mechanical ventilation with tidal volumes of 10mL/kg pre-
dicted body weight. In these patients VALI was diagnosed
after 1.6 ± 0.5 days, after which the ventilator was set to
achieve lung-protective mechanical ventilation with tidal
volumes of 6mL/kg predicted body weight. Ten patients who
did not develop ALI/ARDS served as controls. The base-
line characteristics and admission diagnoses are shown in
Table 1. Patients who developed VALI were sicker, according
to higher SOFA scores, tended to have a higher LIS, and
suﬀered more frequently from sepsis.
3.2. Ventilation Parameters (Figure 1). The period of mech-
anical ventilation before inclusion was comparable between
patients who did and did not develop VALI (22 (14–29)
hours versus 14 (10–21) hours, resp.; P = 0.13). The applied
tidal volumes (10.1 ± 0.7mL/kg versus 9.9 ± 1.3mL/kg
of predicted body weight; P = 0.65; Figure 1), respiratory
rate and minute ventilation were comparable at baseline.
The tidal volume and respiratory rate were adjusted during
the study period in 7 of 10 patients who developed VALI.
The patients who developed VALI already had already higher
requirements for positive end expiratory pressure (PEEP)
Table 1: Baseline characteristics.
VALI
(n = 10)
No VALI
(n = 10) P value
Age (years) 63 (±13) 55 (±11) 0.13
Gender (male) 7 (70%) 6 (60%) 0.64
Duration of mechanical
ventilation before
randomization (hours)
21 (±10) 15 (±7) 0.11
APACHE-II score 20 (±8) 22 (±7) 0.43
SOFA 11 (±4) 7 (±4) 0.03
Lung injury score 1.5 (±0.5) 1.2 (±0.8) 0.37
Diagnosis on admittance
Sepsis 5
Intracranial hemorrhage 5
Aortic dissection 1
Cardiac surgery 1
Heat stroke 1
Resuscitation 2 1
Pneumonia 1
Trauma 2 1
APACHE-II: acute physiology and chronic health evaluation-II; SOFA:
sepsis organ failure assessment score.
at baseline and had concomitant higher maximum airway
pressures (Figure 1). The partial oxygen and carbon dioxide
pressures and pH were comparable at baseline. The partial
oxygen pressure dropped signiﬁcantly after 2 days (P =
0.002) in patients with VALI.
3.3. Pulmonary Coagulation and Fibrinolysis. In patients
who developed VALI activation of pulmonary coagulation
was observed, as reﬂected in a marked increase in TATc
during the course of mechanical ventilation (all P<
0.001 versus day 0; Figure 2). TATc levels increased from
0.89 (0.54–1.26)ng/mL at baseline to a maximum of 3.45
(1.76–4.00)ng/mL after 6 days of mechanical ventilation. In
contrast, in patients who did not develop VALI during the
study pulmonary TATc levels were stable over time (P<
0.001 versus VALI patients).
Thrombin generation appeared to be mediated via the
TF/FVIIa pathway, since marked increases in the local levels
of soluble TF and FVIIa were measured. Soluble TF levels
increasedfrombaseline12.5(11–17.3)pg/mLtoamaximum
of 20.0 (20.0–25.0)pg/mL after 6 days (P<0.001, Figure 2),
whereas FVIIa levels showed a 2-fold increase from 0.75
(0.40–1.13)U/mL before the occurrence of VALI to 1.60
(1.50–1.70)mU/mL after 6 days (P<0.001; Figure 2). Local
levels of soluble TF and FVIIa in patients who did not
develop VALI remained unchanged over time, respectively
(P = 0.01 and P = 0.001 versus VALI patients).
Development of VALI was accompanied by a decreased
ﬁbrinolytic activity in lavage ﬂuids. Local plasminogen acti-
vator activity (PAA) gradually dropped from 87 (78–91) %
to 65 (64–72) % at the day of diagnosis of VALI (P<
0.001, Figure 2) .P A Al e v e l sr e a c h e dan a d i ra t4d a y sa f t e r
the diagnosis of VALI. The decrease in PAA in VALI patients4 Critical Care Research and Practice
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Figure 1: Ventilatory parameters. Tidal volumes per kilogram of predicted body weight (PBW), respiratory rate, positive end expiratory
pressures (PEEP), maximum airway pressures (Pmax), compliance and blood gas analyses data in patients who developed VALI (closed
symbols, n = 10), and patients who did not develop VALI (open symbols, n = 10). Data are mean ± SD. ∗P<0.05.Critical Care Research and Practice 5
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Figure 2: Bronchoalveolar levels of coagulation and ﬁbrinolysis. Thrombin-antithrombin (TATc), soluble tissue factor (TF), factor VIIa
(FVIIa), plasminogen activator activity (PAA) and plasminogen activator inhibitor type 1 (PAI-1) in patients who developed VALI (closed
symbols, n = 10), and patients who did not develop VALI (open symbols, n = 10). Data are medians ± IQR. ∗P<0.05.
appeared to be caused by higher levels of the ﬁbrinolytic
inhibitor PAI-1. PAI-1 levels were already higher at baseline
10.6 (6.4–11.9)ng/mL and gradually increased to a maxi-
mum of 12.3 (9.0–17.4)ng/mL in patients with VALI (P =
0.001). The changes in PAA and PAI-1 were not found in
patientswhodidnotdevelopVALI(P = 0.007andP = 0.003
versus VALI patients, resp.).
3.4. Systemic Hemostasis (Figure 3). Plasma TATc levels were
higher in patients developing VALI during the course of
mechanical ventilation (P<0.001 versus non-VALI patients,
Figure 3). In addition, in patients who developed VALI,
p l a s m aP A Al e v e l sw e r el o w e r( P<0.001 versus patients no
VALI patients). The increase in local TATc levels in patients
developing VALI was not accompanied by a signiﬁcant
i n c r e a s ei ns y s t e m i cT A T cl e v e l s( P = 0.35) Figure 3.
Plasma PAA-levels remained unchanged during the course of
mechanical ventilation (P = 0.99).
4. Discussion
Although mechanical ventilation with lower tidal volumes
is generally considered to be protective in patients with
ALI/ARDS,thereisongoingdebateontheidealtidalvolumes
in patients without preexistent lung injury [16]. We recently
showed that the use of conventional tidal volumes, as
compared to the use of lower tidal volumes, results in a
higher incidence of VALI in patients without ALI/ARDS at
the onset of mechanical ventilation [9]. The present study
extends previous observation that mechanical ventilation
has signiﬁcant eﬀects on bronchoalveolar hemostasis [11].
Indeed, with development of VALI bronchoalveolar coagu-
lopathy ensues, characterized by activation of coagulation on
the one hand and inhibition of ﬁbrinolysis on the other.
Our study has shortcomings. First, we were able to in-
clude only a small number of patients. Indeed, only 10 pa-
tients in the conventional tidal volume arm of the original
study developed VALI [9]. Due to an increased incidence of
VALI in the conventional tidal volume arm, the study was
discontinued after the second interim analysis. At that mo-
ment 150 patients were included and randomized. From an
ethical point of view it is impossible to repeat or continue
the study, thus we will not be able to make our study popu-
lation larger. However, the procoagulant changes are suf-
ﬁciently large enabling us to draw adequate conclusions.6 Critical Care Research and Practice
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Figure 3: Systemic levels of coagulation and ﬁbrinolysis. Thrombin-antithrombin (TATc) and plasminogen activator activity (PAA) in
patients who developed VALI (closed symbols, n = 10), and patients who did not develop VALI (open symbols, n = 10). Data are medians
± IQR. ∗, P<0.05.
Second, it seems that patient selection is not balanced. In-
deed, more patients in the VALI group were suﬀering from
sepsis, which is associated with systemic upregulation of co-
agulation and ﬁbrinolysis parameters [17] and is a well-
known risk factor for ALI/ARDS [18]. In the original study,
however, patient distribution was very well balanced. Al-
though control patients were randomly selected for this sec-
ondary analysis, we are left with this imbalance.
The presently described changes in pulmonary hemosta-
sis are very similar as previously described in patients with
pneumonia or ARDS [13, 19, 20], human volunteers with
endotoxin-induced pulmonary inﬂammation [21, 22], and
patients ventilated with a nonprotective mechanical ven-
tilation mode during surgery [11]. Consistently, increased
procoagulant activity is reported, mostly likely related to the
TF-expression on epithelial cells and mononuclear cells in
the bronchoalveolar compartment. Also, PAI-1 upregulation
has been found consistently in patients with pneumonia or
ARDS [13, 19, 20, 23], human volunteers with endotoxin-
induced pulmonary inﬂammation [21] and patients venti-
lated during surgery with conventional tidal volumes [11].
Although in the settings of endotoxin-induced pulmonary
inﬂammation and short-term mechanical ventilation during
surgery, no suppression of ﬁbrinolytic activity was observed,
the present study shows that prolonged mechanical ventila-
tion could lead to more interference with ﬁbrinolytic system.
One important observation in the present study is that
pulmonary coagulopathy was already present at baseline.
Indeed, at baseline bronchoalveolar PAI-1 levels were already
increased in patients who developed VALI. This may be
related to the fact that 5 patients were septic and therefore
had elevated PAI-1 levels in the blood and lungs. Moreover,
although not signiﬁcant, the patients from the VALI group
had been ventilated 6 hours longer before randomization.
Bronchoalveolar lavage ﬂuid and plasma samples were there-
fore obtained after a longer period of mechanical ventilation
in these patients which may have resulted in higher levels
of PAI-1. These patients did not have clinically apparent
ALI/ARDS but it is likely that in these patients beginning
subclinical lung injury was present at the time of randomiza-
tion. A “multiple-hit” model of lung injury can be theorized
whereby predisposing conditions, like injurious mechanical
ventilation, may result in pulmonary inﬂammation (the
“primary hit”). Then, several “second hits” (not per se hap-
pening in a consecutive manner, i.e., following the ﬁrst hit,
but maybe or sometimes even likely at the same time), like
transfusion of blood products [24], aspiration [2, 25], shock
or sepsis [2, 25], and ventilator-associated pneumonia [26],
may all cause additional lung injury, ﬁnally resulting in full-
blown ARDS with high morbidity and mortality.
Earlier studies have shown PAI-1 to be a biomarker of
ALI/ARDS. Systemic levels of PAI-1 have been shown to be
prognostic in ALI/ARDS patients [27]. The highest levels
were observed in patients with the worst outcomes. More-
over, bronchoalveolar PAI-1 levels have also been shown to
be diagnostic of ALI/ARDS in patients with aspiration pneu-
monia [28]. These observations imply that elevated pul-
monary PAI-1 levels are indeed associated with lung injury.
It is therefore likely that our patients with VALI already had
had a ﬁrst hit that caused local PAI-1 levels to increase.
All of the described eﬀects shift the hemostatic balance
towards a procoagulant side, promoting ﬁbrin depositions
in the airways. The question remains whether this reﬂects
an adaptive mechanism with host protective functions, or
whether it is a harmful process, predisposing the lungs to
secondary complications or perhaps long-term eﬀects onCritical Care Research and Practice 7
pulmonary function. Fibrin deposition may be an important
mechanism to repair endothelial or epithelial damage, how-
ever an exaggerated coagulation activation has been related
to a number of detrimental sequelae.
We here demonstrate that VALI in patients with normal
lungs at the onset of mechanical ventilation is characterized
by a procoagulant shift in the bronchoalveolar hemostatic
balance.OurresultsshowthatitislikelythatVALIdeveloped
in patients who had had a primary hit. Monitoring coagu-
lation parameters like PAI-1 may be helpful in determining
which patients are at risk for VALI.
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